The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
ExCITE 计划:加速商业化、创新、翻译、
基本信息
- 批准号:9038438
- 负责人:
- 金额:$ 99.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-03-20 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcademiaAntineoplastic AgentsAwardBackBasic ScienceBiomedical ResearchBusinessesCenters of Research ExcellenceClinical TrialsComplementDevelopmentDevelopment PlansDevicesEconomic DevelopmentEducationEducational process of instructingEnsureEntrepreneurshipEnvironmentEvaluationFacultyFederal GovernmentFundingGoalsGraft RejectionGrantHealthHumanIncomeIncubatorsIndustryInstitutionIntellectual PropertyInterventionInvestmentsKentuckyKnowledgeLeadershipLettersMalignant NeoplasmsMarketingMentorsMentorshipMethodsMissionMonitorNatureParaplegiaPatientsPositioning AttributePrivate SectorProblem SolvingProtocols documentationResearchResearch InfrastructureResearch PersonnelResourcesScientistSeriesSourceSpeedStructureSystemTalentsTechnologyTechnology TransferTestingTimeTranslatingTranslational ResearchTranslationsUnited States National Institutes of HealthUniversitiesWorkbasebench to bedsidebiosafety level 3 facilityclinically relevantcommercializationdesigneconomic impacteducation accessexperiencehuman diseaseimprovedinnovationmemberminimally invasivenovel vaccinesoperationpreventprogramspublic-private partnershipsuccesstechnology development
项目摘要
DESCRIPTION (provided by applicant): The overarching goal of this project is to increase the success rate and speed with which the results of basic biomedical research are translated into products that have a positive impact on human health. To do this, we propose to create a commercialization program at the University of Louisville (UofL) with a structure that is designed to overcome the many obstacles that currently impede translation. Though UofL is a relatively small institution in an IDeA state, it has invested in talent and infrastructure for translational research in order to create a pro-entrepreneurial culture. This has already paid dividends and UofL has been awarded numerous major grants, including three current COBRE awards, a Coulter Translational Partnership, the NIH Cardioprotection Consortium, the NIH-UofL RBL (a BSL-3 facility), and multiple P-/U- series grants. Moreover, UofL discoveries have led to interventions that have already benefited patients, such as a first-in- class anticancer drug, a method to prevent transplant rejection, and a protocol that has allowed paraplegic patients to stand again. Many more UofL innovations are now on their way to clinical trials, including new vaccines and minimally invasive devices to detect cancer. The proposed UofL REACH program will be known as "the ExCITE Hub" to reflect its function as a central resource for Expediting Commercialization, Innovation, Translation, and Entrepreneurship. The hub is designed to fulfill the goals of the FOA (RFA-OD- 14-005), but is tailored to match UofL's specific strengths and needs. In short, the university will supply a robust pipeline of diverse technologies and the infrastructure/expertise required for translational research, whereas the Hub will deliver the necessary funding, education, and access to business expertise to bridge the gap between a great idea and the marketplace. The ExCITE Hub has three major aims: (1) identify the most promising technologies and provide funding for product definition studies, (2) promote commercialization of selected products and transition to a self-sustaining ExCITE program, and (3) expand educational, experiential, and networking opportunities for stakeholders. Our approach includes innovative features: (1) a geographically focused program to expedite operations and maximize impact on the local eco-system, (2) an innovative governance structure to integrate the three main goals and avoid silos, (3) a proactive, rather than passive, approach to education, (4) a mentored technology development grant program that requires early interactions between scientists, tech transfer staff, and industry consultants, and (5) an emphasis on improving academia-industry relationships by increasing mutual understanding, ensuring robust technologies, and being responsive to industry needs. Institutional and regional commitment to the ExCITE Hub is evident from the >$3.1M in matching funds and 40 letters of support. Success in this project will have a major economic impact on the region and will speed the delivery of innovative new products to the patients that need them.
该项目的总体目标是提高基础生物医学研究成果转化为对人类健康产生积极影响的产品的成功率和速度。为此,我们建议在路易斯维尔大学(UofL)创建一个商业化项目,其结构旨在克服目前阻碍翻译的许多障碍。虽然UofL在IDEA州是一个相对较小的机构,但它已经投资于转化研究的人才和基础设施,以创造一个支持创业的文化。这已经支付了股息,UofL已经获得了许多重大赠款,包括三个当前的COBRE奖,库尔特翻译合作伙伴关系,NIH生物保护联盟,NIH-UofL RBL(BSL-3设施)和多个P-/U-系列赠款。此外,UofL的发现已经导致了已经使患者受益的干预措施,例如一流的抗癌药物,防止移植排斥的方法,以及允许截瘫患者再次站立的方案。更多UofL的创新现在正在进行临床试验,包括新疫苗和检测癌症的微创设备。拟议的UofL REACH计划将被称为“ExCITE Hub”,以反映其作为加速商业化,创新,翻译和创业的中心资源的功能。该中心的设计是为了实现FOA(RFA-OD- 14-005)的目标,但量身定制,以匹配UofL的具体优势和需求。简而言之,大学将提供多样化技术和转化研究所需的基础设施/专业知识的强大管道,而中心将提供必要的资金,教育和获得商业专业知识,以弥合伟大想法和市场之间的差距。ExCITE Hub有三个主要目标:(1)确定最有前途的技术并为产品定义研究提供资金,(2)促进选定产品的商业化并过渡到自我维持的ExCITE计划,以及(3)为利益相关者扩大教育,体验和网络机会。我们的方法包括创新功能:(1)一个以地理为重点的计划,以加快运营并最大限度地提高对当地生态系统的影响,(2)一个创新的治理结构,以整合三个主要目标并避免孤岛,(3)一个积极主动的,而不是被动的教育方法,(4)一个指导性的技术开发赠款计划,需要科学家,技术转让人员,和行业顾问,以及(5)通过增加相互理解,确保强大的技术,并对行业需求做出反应,强调改善企业与行业的关系。从超过310万美元的配套资金和40封支持信中可以看出机构和区域对Excite Hub的承诺。该项目的成功将对该地区产生重大的经济影响,并将加快向有需要的患者提供创新产品。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paula J. Bates其他文献
Paula J. Bates的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paula J. Bates', 18)}}的其他基金
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
肯塔基州创新网络
- 批准号:
9897157 - 财政年份:2019
- 资助金额:
$ 99.92万 - 项目类别:
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
肯塔基州创新网络
- 批准号:
10022341 - 财政年份:2019
- 资助金额:
$ 99.92万 - 项目类别:
Kentucky Network for Innovation & Commercialization (“KYNETIC”)
肯塔基州创新网络
- 批准号:
10240675 - 财政年份:2019
- 资助金额:
$ 99.92万 - 项目类别:
A Role for Nucleolin in Malignant Transformation?
核仁素在恶性转化中的作用?
- 批准号:
6826563 - 财政年份:2004
- 资助金额:
$ 99.92万 - 项目类别:
A Role for Nucleolin in Malignant Transformation?
核仁素在恶性转化中的作用?
- 批准号:
6933846 - 财政年份:2004
- 资助金额:
$ 99.92万 - 项目类别:
相似海外基金
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
- 批准号:
9975367 - 财政年份:2020
- 资助金额:
$ 99.92万 - 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
- 批准号:
16K11932 - 财政年份:2016
- 资助金额:
$ 99.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
- 批准号:
19591274 - 财政年份:2007
- 资助金额:
$ 99.92万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
- 批准号:
6346309 - 财政年份:2000
- 资助金额:
$ 99.92万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
2885074 - 财政年份:1999
- 资助金额:
$ 99.92万 - 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
- 批准号:
6174221 - 财政年份:1999
- 资助金额:
$ 99.92万 - 项目类别: